A Combination Study of Flotetuzumab and MGA012 (an anti-PD-1 monoclonal antibody) in Patients with Acute Myeloid-Leukaemia (AML)

Trial Profile

A Combination Study of Flotetuzumab and MGA012 (an anti-PD-1 monoclonal antibody) in Patients with Acute Myeloid-Leukaemia (AML)

Planning
Phase of Trial: Phase I

Latest Information Update: 07 May 2018

At a glance

  • Drugs Flotetuzumab (Primary) ; INCMGA 0012 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 May 2018 According to a MacroGenics media release, the company intends to initiate this combination study in third quarter of 2018.
    • 01 Mar 2018 New trial record
    • 27 Feb 2018 According to a MacroGenics media release, the company intends to initiate this combination study by mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top